New York Canna Cometh

A timeline emerges for the Empire State.

Daily Recap

Proposed settlement terms for the legal dispute that has exemplified disrupted the New York cannabis market were released today and while they won’t be final until they’re formally accepted by the NY Supreme Court, the stage is now set for state-licensed MSOs to sell adult-use cannabis in the next few weeks.

Pot Over Pills

A recent study revealed that the average change in a pharma company's market value for each time a state legalized either medical or adult-use cannabis was $63M and that the cumulative impact on the pharmaceutical industry is roughly $9.8 billion.

"This implies a change in annual sales across all drug-makers of $3B per state-level legalization event," reported the study's authors. They also noted that the level of sales decrease is 129% greater for adult-use legalization versus medical programs.

Viking Funeral

Minnesota’s top marijuana regulator expects the state to launch adult-use sales in early 2025 as previously planned despite several key administrative positions still unfulfilled and the continued need to finalize the program rules and requirements.

Marcel Marceau

It’s whisper thin across the market surface but there’s lot’s happening beneath the hood. We’ll dive into some of that below, including New York particulars, timing of DEA, likelihood of SAFE, fresh technical takes + a visit from some old friends.

All that and more, just scroll down.

SPY 0.00%↑ QQQ 0.00%↑ IWM 0.00%↑ MSOS 0.00%↑ PT Notional: $53M

Top Stories